Does Wegovy lower your heart rate — and should you be concerned?

Does semaglutide raise or lower heart rate, what do the trials show?

This is one of the most common points of confusion around Wegovy, and it is worth clearing up plainly: the predominant signal in clinical trial data is a modest increase in resting heart rate, not a decrease. The STEP 1 trial, published in the New England Journal of Medicine, followed adults over 68 weeks and recorded changes in multiple cardiovascular markers. Across the semaglutide arm, resting heart rate nudged upward by roughly one to three beats per minute on average, a change so small most participants were unaware of it.

GLP-1 receptor agonists as a class act partly through the autonomic nervous system, and this mild chronotropic effect (increasing the rate at which the heart beats) is a known pharmacological property rather than a side-effect exclusive to people with a pre-existing condition. It tends to appear in the first weeks of treatment. Worth knowing: this is separate from the cardiovascular protection data, which is a different question altogether and relates to events like heart attacks and strokes, not pulse rate.

The NHS medicines information for semaglutide notes heart rate changes among the effects that have been observed during treatment. NHS patient-level guidance on semaglutide recommends telling your doctor or pharmacist if you notice a rapid or irregular heartbeat.

If semaglutide raises heart rate, why do some people's pulse fall over time?

This is where the picture gets more interesting. The direct pharmacological nudge upward exists, but so does a separate, powerful biological force pushing in the opposite direction: weight loss. Carrying excess weight increases the workload on the heart. As body mass reduces (and Wegovy produces meaningful reductions for many people on treatment) resting heart rate often falls in parallel. In practice, for people who lose significant weight, the net long-term effect on their resting pulse can end up neutral or even slightly lower than when they started.

This is not a contradiction; it is two mechanisms operating simultaneously. Which one dominates depends on how much weight is lost, how quickly, and individual cardiovascular factors. Some people see a small early rise then a gradual normalisation. Others notice nothing measurable. A smaller number, particularly those with pre-existing arrhythmias, may find the change clinically significant, which is why prescribers take a full medical history before approving treatment. If you have been wondering about the eligibility rules that apply in specific health situations, a prescriber review is the right place to work through those nuances.

It is also worth noting that heart rate is sensitive to all sorts of day-to-day variables: hydration, caffeine, sleep quality, and activity level. A reading taken at home after a brisk walk tells you very little on its own.

When should a pulse change on Wegovy prompt medical attention?

A one-to-three beat-per-minute increase that settles after the first few weeks is not, on its own, a cause for alarm. The signals worth acting on are different in character: a rapid or pounding heartbeat that feels uncomfortable, an irregular rhythm (a fluttering or skipping sensation in the chest), dizziness or near-fainting, or chest pain. These warrant prompt contact with a GP or, if severe, 999.

Persistent tachycardia (a resting heart rate consistently above 100 beats per minute) should also be discussed with a prescriber, particularly if it appears shortly after starting or increasing the dose. People who monitor their heart rate regularly through a smartwatch may notice transient elevations that resolve on their own; discuss patterns, not single readings, with your clinical team. For anyone using Wegovy privately, accessing our aftercare team is the right first step rather than adjusting the dose independently.

Side effects, including cardiovascular ones, can be reported through the MHRA Yellow Card scheme, this matters both for individual safety and for the broader evidence base that regulators use to monitor medicines post-approval. Semaglutide carries a Black Triangle (▼) status, meaning the MHRA collects all adverse event reports with particular interest. If you have questions about what side effects to watch for more broadly, our frequently asked questions cover the most common concerns.

Does any of this affect whether you are eligible for Wegovy?

Not in isolation. A mildly elevated resting heart rate is not an automatic barrier to treatment, though a prescriber will want to understand the full picture: your baseline pulse, any history of arrhythmia, current medications that already affect heart rate (beta-blockers, for instance), and whether you have any structural heart conditions. If you want a closer look at how Wegovy interacts with heart rate across different patient profiles, that detail is worth reviewing before your consultation. The licence for Wegovy covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, but the licensed BMI threshold is only the starting point. Prescribers assess individual suitability, not just numbers on a form.

For context on what private Wegovy treatment involves in terms of cost and process, that information sits separately. What matters here is that cardiovascular safety is a standard part of the clinical assessment, not an afterthought. A thorough prescriber review exists precisely to catch situations where the expected risk-benefit balance shifts for a particular person.

The full overview of Wegovy as a treatment covers the broader evidence, eligibility criteria and what the treatment pathway looks like from start to finish. If you are ready to find out whether Wegovy is appropriate for you, a prescriber at our clinical team reviews every consultation the same day. You can also read more about whether and how Wegovy affects heart rate and, for those with specific concerns about speed of onset, there is further detail on whether Wegovy causes a fast heart rate.